SlideShare ist ein Scribd-Unternehmen logo
1 von 1
Downloaden Sie, um offline zu lesen
Nephrotex Dialysis MembraneTeam members: Pierce Hadley
Kunal Berry Katherine Kiang
Caroline Blassick Hannah Kuhl
Summary of Decision
Radar Graph for Selected Prototypes
Summary of Design Process Results from Testing
Group C, Team 2
A dialyzer is a medical device used for performing
hemodialysis mechanically through a porous membrane. A
dialyzer consists of solution-filled tube surrounding a
membrane, through which blood is pumped [1].
Hemodialysis uses diffusion, or the flow of a substance
from areas of high to low concentration, to act as a
mechanical kidney for those whose kidneys don't properly
function [2]. Hemodialysis has two main functions: To
remove metabolic waste from the blood and to maintain
water- electrolyte balance in the body. Electrolytes are
chemicals, such as potassium, chlorine, and sodium, that
dissolve in blood and perform a number of important
biological functions [1], [3].
Although hemodialysis has been practiced for decades,
hemodialysis patients continue to show lower quality of
life and higher risk of mortality than the general
population, prompting the need for faster and safer
hemodialysis [4], [5].
Our goal was to improve dialysis patients’ safety and
quality of life by creating a more efficient, cost-effective,
and safe dialysis membrane by experimenting with
different materials, surfactants, manufacturing processes,
and carbon nanotube (CNT) concentrations. A surfactant
is a material applied to the surface of the membrane to
improve performance by allowing organic compounds to
dissolve more easily, while carbon nanotubes are
cylindrical carbon molecules useful in improving the flow
rate and reliability of a dialysis membrane [6].
Hydrophilic
surfactant adds
reliability to our
design while
minimizing cost
Material Reliability Marketability Cost Flux Rate Blood Cell
Reactivity
PMMA N/A N/A N/A N/A N/A
PSF 7 500,000 90 21 65.56
PESPVP 11 600,000 130 13 43.33
PAM 9 600,000 110 19 43.33
PRNLT 9 800,000 130 21 65.56
2% Carbon Nanotube
Concentration maximizes flux
and provides a good balance
of reliability and marketability
PAM (Polyamide)
material may be high
cost, but it provides
excellent flux and blood
cell reactivity
The Dry-jet Wet
manufacturing process
reduces cost without
bringing blood cell reactivity
and flux too low.
# Material Process Surfactant % CNT
1 PMMA Phase Steric Hindrance 6.0
2 PSF Phase Steric Hindrance 1.0
3 PESPVP Vapor Steric Hindrance 15.0
4 PAM Dry Jet Wet Hydrophilic 2.0
5 PRNLT Dry Jet Wet Steric Hindrance 4.0
[1] Nephrotex, How Dialysis Works , Background research on dialysis , p.1 - 1
[2] Nephrotex, Introduction to Diffusion , Background research on dialysis , p.1 - 1
[3] Kirschbaum, B , The effect of hemodialysis on electrolytes and acid–base parameters , Clinica Chimica Acta , vol
336 , no 1-2, p.109 - 113
[4] Kalantar-Zadeh, K, Association Among SF36 Quality of Life Measures and Nutrition, Hospitalization, and
Mortality in Hemodialysis , Journal of the American Society of Nephrology , vol 12 , no 12, p.2797 - 2806
[5] Guerini, R , Multidimensional health-status assessment of chronic hemodialysis patients: the impact on quality
of life. , Europa Medicophysica , vol 42 , no 2, p.113 - 119
[6] Nephrotex, Hemodialytic Filtration Glossary, Background research on dialysis , p.1 - 3
[7] Nephrotex, Summary of Five Attributes, Graphing Surfactant Data , p.1 - 1
[8] Delgado, A , "Internal Consultants' Requests". RetrievedNovember , 2014 Available:
Image Credits:
[Image 1] "How Dialysis Works" Www.nephrotex.com. Web. 22 Nov. 2014.
[Image 2] "Introduction to Diffusion." Www.nephrotex.com. Web. 22 Nov. 2014.
[Image 3] “Radar Graph from FEEDS testing.” www.nephrotex.com. N.p., n.d. Web.
[Image 4] “Membrane Diagram from FEEDS.” www.nephrotex.com. N.p., n.d. Web.
Background: "Dna_desktop_1920x1080_hd-wallpaper." Http://www.hdwallpaperspics.com. Web. 22 Nov. 2014
Reliability: Refers to how long a dialysis membrane can perform before
falling below 75% of its maximum flux. Reliability is measured in hours
[7].
Marketability: Measures the expected commercial success of the
prototype, on a point scale [7].
Cost: Expense required to produce each unit, measured in dollars [7].
Flux Rate: Measures how quickly blood flows through the dialysis
membrane. Measured in m^3 / (m^2 - day) [7].
Blood Cell Reactivity: Measures the body’s immune response during
hemodialysis, in units of nanograms of activated blood components per
milliliter [7].
The PAM prototype was chosen for meeting
the highest number of consultants’
preferred values in addition to all of their
basic requirements. Although the prototype
failed to meet one preferred requirement in
cost, marketability, and blood cell reactivity,
it was close to the cutoff point in all cases.
The product’s high flux means faster
treatment time for the patient, while its low
cost and blood cell reactivity result in safe
and affordable care. With the addition of its
high marketability, the PAM prototype
provides the perfect balance between
business success and patient satisfaction.
Summary of System Testing Criteria
This prototype was developed in a multi-stage process. Each member of the
design team came in with knowledge of a particular membrane material,
which was based off of prototype testing with another group. After a group
meeting outlining the design goals and criteria, each member used this
knowledge to create the best design they could. Then each design was tested
in Nephrotex’s Electronic Experimental Device Simulator in order to find
which material design prototype had the best results.
Design Diagram
Above: A diagram illustrating blood flow
through the dialyzer [Image 1].
Below: Dialysis membrane allow waste
and electrolytes to diffuse while keeping
blood cells inside the bloodstream [Image
2].
[Image 3]
[Image 4]
Design
Attribute
Required Values for
Each Consultant [8]
Preferred Values for
Each Consultant [8]
Met by Prototype?
Reliability >1.5 (Michelle)
>5 (Alan)
>8 (Michelle)
>9 (Alan)
All
Marketability >250,000 (Wayne)
>400,000 (Rudy)
>650,000 (Wayne)
>550,000 (Rudy)
All but Wayne’s
Preferred
Cost <$120 (Rudy)
<$140 (Alan)
<$110 (Rudy)
<$95 (Alan)
All but Rudy’s
Preferred
Flux Rate >10 (Padma)
>12 (Michelle)
>17 (Padma)
>13.5 (Michelle)
All
Blood Cell
Reactivity
>75 (Padma)
>90 (Michelle)
>40(Padma)
>65 (Michelle)
All but Padma’s
Preferred
References

Weitere ähnliche Inhalte

Ähnlich wie poster_template.pptx

Study of Microfluidics and its Application in Biomedical Diagnostic Devices
Study of Microfluidics and its Application in Biomedical Diagnostic DevicesStudy of Microfluidics and its Application in Biomedical Diagnostic Devices
Study of Microfluidics and its Application in Biomedical Diagnostic DevicesAngshuman Pal
 
Nanorobots in the medicinal world my ieee
Nanorobots in the medicinal world my ieeeNanorobots in the medicinal world my ieee
Nanorobots in the medicinal world my ieeeSindhu Nathan
 
Nanorobots in the medicinal world my ieee
Nanorobots in the medicinal world my ieeeNanorobots in the medicinal world my ieee
Nanorobots in the medicinal world my ieeepriyasindhu
 
Launching digital biology, 12 May 2015, Bremen
Launching digital biology, 12 May 2015, BremenLaunching digital biology, 12 May 2015, Bremen
Launching digital biology, 12 May 2015, Bremenbioflux
 
HDMICS WSS Koutsiaris 2007
HDMICS WSS Koutsiaris 2007HDMICS WSS Koutsiaris 2007
HDMICS WSS Koutsiaris 2007Koutsiaris Aris
 
Challenges in Clinical Trials Networks
Challenges in Clinical Trials NetworksChallenges in Clinical Trials Networks
Challenges in Clinical Trials NetworksUS Cochrane Center
 
Chris worledgeportfolio
Chris worledgeportfolioChris worledgeportfolio
Chris worledgeportfolioChris Worledge
 
Reverse electro-dialysis in desalination process
Reverse electro-dialysis in desalination processReverse electro-dialysis in desalination process
Reverse electro-dialysis in desalination processJinit1
 
Human erythrocyte filterability at low driving pressure version 7.1
Human erythrocyte filterability at low driving pressure   version 7.1Human erythrocyte filterability at low driving pressure   version 7.1
Human erythrocyte filterability at low driving pressure version 7.1Shay Ginsbourg
 
Flow Cytometry in Microfluidics
Flow Cytometry in MicrofluidicsFlow Cytometry in Microfluidics
Flow Cytometry in MicrofluidicsSaransh Khandelwal
 
DT222 steven gribbin placement poster 2015 Ver 2
DT222 steven gribbin placement poster 2015 Ver 2DT222 steven gribbin placement poster 2015 Ver 2
DT222 steven gribbin placement poster 2015 Ver 2Steven Gribbin
 
Mitra Microsampling Technology
Mitra Microsampling TechnologyMitra Microsampling Technology
Mitra Microsampling TechnologyTom Wingert
 
Sk microfluidics and lab on-a-chip-ch5
Sk microfluidics and lab on-a-chip-ch5Sk microfluidics and lab on-a-chip-ch5
Sk microfluidics and lab on-a-chip-ch5stanislas547
 
Group4.plasma surface modification of polylactic acid to promote
Group4.plasma surface modification of polylactic acid to promoteGroup4.plasma surface modification of polylactic acid to promote
Group4.plasma surface modification of polylactic acid to promoteRoy Rodriguez Solano
 
C1LC20622B (1)
C1LC20622B (1)C1LC20622B (1)
C1LC20622B (1)Gen Vigil
 
Ab experiments of fluid flow in polymer microchannel
Ab experiments of fluid flow in polymer microchannelAb experiments of fluid flow in polymer microchannel
Ab experiments of fluid flow in polymer microchannelShaelMalik
 
nanocellulose based medicine 2017 Rev 3rd Article.pdf
nanocellulose based medicine 2017 Rev 3rd Article.pdfnanocellulose based medicine 2017 Rev 3rd Article.pdf
nanocellulose based medicine 2017 Rev 3rd Article.pdftanveercdr
 
Owen Burns_UOW_Thesis A_2008
Owen Burns_UOW_Thesis A_2008Owen Burns_UOW_Thesis A_2008
Owen Burns_UOW_Thesis A_2008Owen Burns
 

Ähnlich wie poster_template.pptx (20)

Study of Microfluidics and its Application in Biomedical Diagnostic Devices
Study of Microfluidics and its Application in Biomedical Diagnostic DevicesStudy of Microfluidics and its Application in Biomedical Diagnostic Devices
Study of Microfluidics and its Application in Biomedical Diagnostic Devices
 
Nanorobots in the medicinal world my ieee
Nanorobots in the medicinal world my ieeeNanorobots in the medicinal world my ieee
Nanorobots in the medicinal world my ieee
 
Nanorobots in the medicinal world my ieee
Nanorobots in the medicinal world my ieeeNanorobots in the medicinal world my ieee
Nanorobots in the medicinal world my ieee
 
Launching digital biology, 12 May 2015, Bremen
Launching digital biology, 12 May 2015, BremenLaunching digital biology, 12 May 2015, Bremen
Launching digital biology, 12 May 2015, Bremen
 
HDMICS WSS Koutsiaris 2007
HDMICS WSS Koutsiaris 2007HDMICS WSS Koutsiaris 2007
HDMICS WSS Koutsiaris 2007
 
Challenges in Clinical Trials Networks
Challenges in Clinical Trials NetworksChallenges in Clinical Trials Networks
Challenges in Clinical Trials Networks
 
Chris worledgeportfolio
Chris worledgeportfolioChris worledgeportfolio
Chris worledgeportfolio
 
Reverse electro-dialysis in desalination process
Reverse electro-dialysis in desalination processReverse electro-dialysis in desalination process
Reverse electro-dialysis in desalination process
 
Human erythrocyte filterability at low driving pressure version 7.1
Human erythrocyte filterability at low driving pressure   version 7.1Human erythrocyte filterability at low driving pressure   version 7.1
Human erythrocyte filterability at low driving pressure version 7.1
 
Flow Cytometry in Microfluidics
Flow Cytometry in MicrofluidicsFlow Cytometry in Microfluidics
Flow Cytometry in Microfluidics
 
DT222 steven gribbin placement poster 2015 Ver 2
DT222 steven gribbin placement poster 2015 Ver 2DT222 steven gribbin placement poster 2015 Ver 2
DT222 steven gribbin placement poster 2015 Ver 2
 
Mitra Microsampling Technology
Mitra Microsampling TechnologyMitra Microsampling Technology
Mitra Microsampling Technology
 
40120140502011
4012014050201140120140502011
40120140502011
 
FDR Presentation
FDR PresentationFDR Presentation
FDR Presentation
 
Sk microfluidics and lab on-a-chip-ch5
Sk microfluidics and lab on-a-chip-ch5Sk microfluidics and lab on-a-chip-ch5
Sk microfluidics and lab on-a-chip-ch5
 
Group4.plasma surface modification of polylactic acid to promote
Group4.plasma surface modification of polylactic acid to promoteGroup4.plasma surface modification of polylactic acid to promote
Group4.plasma surface modification of polylactic acid to promote
 
C1LC20622B (1)
C1LC20622B (1)C1LC20622B (1)
C1LC20622B (1)
 
Ab experiments of fluid flow in polymer microchannel
Ab experiments of fluid flow in polymer microchannelAb experiments of fluid flow in polymer microchannel
Ab experiments of fluid flow in polymer microchannel
 
nanocellulose based medicine 2017 Rev 3rd Article.pdf
nanocellulose based medicine 2017 Rev 3rd Article.pdfnanocellulose based medicine 2017 Rev 3rd Article.pdf
nanocellulose based medicine 2017 Rev 3rd Article.pdf
 
Owen Burns_UOW_Thesis A_2008
Owen Burns_UOW_Thesis A_2008Owen Burns_UOW_Thesis A_2008
Owen Burns_UOW_Thesis A_2008
 

poster_template.pptx

  • 1. Nephrotex Dialysis MembraneTeam members: Pierce Hadley Kunal Berry Katherine Kiang Caroline Blassick Hannah Kuhl Summary of Decision Radar Graph for Selected Prototypes Summary of Design Process Results from Testing Group C, Team 2 A dialyzer is a medical device used for performing hemodialysis mechanically through a porous membrane. A dialyzer consists of solution-filled tube surrounding a membrane, through which blood is pumped [1]. Hemodialysis uses diffusion, or the flow of a substance from areas of high to low concentration, to act as a mechanical kidney for those whose kidneys don't properly function [2]. Hemodialysis has two main functions: To remove metabolic waste from the blood and to maintain water- electrolyte balance in the body. Electrolytes are chemicals, such as potassium, chlorine, and sodium, that dissolve in blood and perform a number of important biological functions [1], [3]. Although hemodialysis has been practiced for decades, hemodialysis patients continue to show lower quality of life and higher risk of mortality than the general population, prompting the need for faster and safer hemodialysis [4], [5]. Our goal was to improve dialysis patients’ safety and quality of life by creating a more efficient, cost-effective, and safe dialysis membrane by experimenting with different materials, surfactants, manufacturing processes, and carbon nanotube (CNT) concentrations. A surfactant is a material applied to the surface of the membrane to improve performance by allowing organic compounds to dissolve more easily, while carbon nanotubes are cylindrical carbon molecules useful in improving the flow rate and reliability of a dialysis membrane [6]. Hydrophilic surfactant adds reliability to our design while minimizing cost Material Reliability Marketability Cost Flux Rate Blood Cell Reactivity PMMA N/A N/A N/A N/A N/A PSF 7 500,000 90 21 65.56 PESPVP 11 600,000 130 13 43.33 PAM 9 600,000 110 19 43.33 PRNLT 9 800,000 130 21 65.56 2% Carbon Nanotube Concentration maximizes flux and provides a good balance of reliability and marketability PAM (Polyamide) material may be high cost, but it provides excellent flux and blood cell reactivity The Dry-jet Wet manufacturing process reduces cost without bringing blood cell reactivity and flux too low. # Material Process Surfactant % CNT 1 PMMA Phase Steric Hindrance 6.0 2 PSF Phase Steric Hindrance 1.0 3 PESPVP Vapor Steric Hindrance 15.0 4 PAM Dry Jet Wet Hydrophilic 2.0 5 PRNLT Dry Jet Wet Steric Hindrance 4.0 [1] Nephrotex, How Dialysis Works , Background research on dialysis , p.1 - 1 [2] Nephrotex, Introduction to Diffusion , Background research on dialysis , p.1 - 1 [3] Kirschbaum, B , The effect of hemodialysis on electrolytes and acid–base parameters , Clinica Chimica Acta , vol 336 , no 1-2, p.109 - 113 [4] Kalantar-Zadeh, K, Association Among SF36 Quality of Life Measures and Nutrition, Hospitalization, and Mortality in Hemodialysis , Journal of the American Society of Nephrology , vol 12 , no 12, p.2797 - 2806 [5] Guerini, R , Multidimensional health-status assessment of chronic hemodialysis patients: the impact on quality of life. , Europa Medicophysica , vol 42 , no 2, p.113 - 119 [6] Nephrotex, Hemodialytic Filtration Glossary, Background research on dialysis , p.1 - 3 [7] Nephrotex, Summary of Five Attributes, Graphing Surfactant Data , p.1 - 1 [8] Delgado, A , "Internal Consultants' Requests". RetrievedNovember , 2014 Available: Image Credits: [Image 1] "How Dialysis Works" Www.nephrotex.com. Web. 22 Nov. 2014. [Image 2] "Introduction to Diffusion." Www.nephrotex.com. Web. 22 Nov. 2014. [Image 3] “Radar Graph from FEEDS testing.” www.nephrotex.com. N.p., n.d. Web. [Image 4] “Membrane Diagram from FEEDS.” www.nephrotex.com. N.p., n.d. Web. Background: "Dna_desktop_1920x1080_hd-wallpaper." Http://www.hdwallpaperspics.com. Web. 22 Nov. 2014 Reliability: Refers to how long a dialysis membrane can perform before falling below 75% of its maximum flux. Reliability is measured in hours [7]. Marketability: Measures the expected commercial success of the prototype, on a point scale [7]. Cost: Expense required to produce each unit, measured in dollars [7]. Flux Rate: Measures how quickly blood flows through the dialysis membrane. Measured in m^3 / (m^2 - day) [7]. Blood Cell Reactivity: Measures the body’s immune response during hemodialysis, in units of nanograms of activated blood components per milliliter [7]. The PAM prototype was chosen for meeting the highest number of consultants’ preferred values in addition to all of their basic requirements. Although the prototype failed to meet one preferred requirement in cost, marketability, and blood cell reactivity, it was close to the cutoff point in all cases. The product’s high flux means faster treatment time for the patient, while its low cost and blood cell reactivity result in safe and affordable care. With the addition of its high marketability, the PAM prototype provides the perfect balance between business success and patient satisfaction. Summary of System Testing Criteria This prototype was developed in a multi-stage process. Each member of the design team came in with knowledge of a particular membrane material, which was based off of prototype testing with another group. After a group meeting outlining the design goals and criteria, each member used this knowledge to create the best design they could. Then each design was tested in Nephrotex’s Electronic Experimental Device Simulator in order to find which material design prototype had the best results. Design Diagram Above: A diagram illustrating blood flow through the dialyzer [Image 1]. Below: Dialysis membrane allow waste and electrolytes to diffuse while keeping blood cells inside the bloodstream [Image 2]. [Image 3] [Image 4] Design Attribute Required Values for Each Consultant [8] Preferred Values for Each Consultant [8] Met by Prototype? Reliability >1.5 (Michelle) >5 (Alan) >8 (Michelle) >9 (Alan) All Marketability >250,000 (Wayne) >400,000 (Rudy) >650,000 (Wayne) >550,000 (Rudy) All but Wayne’s Preferred Cost <$120 (Rudy) <$140 (Alan) <$110 (Rudy) <$95 (Alan) All but Rudy’s Preferred Flux Rate >10 (Padma) >12 (Michelle) >17 (Padma) >13.5 (Michelle) All Blood Cell Reactivity >75 (Padma) >90 (Michelle) >40(Padma) >65 (Michelle) All but Padma’s Preferred References